Fund+ is a Leuven open-ended fund making long-term equity investments in innovative life sciences companies with a focus on Belgium. It took part in Ona Therapeutics' $86.6M Series B (June 2026) and Novadip's €10.4M financing (September 2026).
Website reachable as of Sept 2026. Focus and check size as listed by the firm, not independently verified.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.